Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02098499
Other study ID # NMCP.2012.0008
Secondary ID
Status Completed
Phase Phase 4
First received March 17, 2014
Last updated March 27, 2014
Start date June 2013
Est. completion date February 2014

Study information

Verified date March 2014
Source United States Naval Medical Center, Portsmouth
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

Haloperidol is known to be a safe alternative medication to control difficult pain, and has been shown effective when compared to placebo for controlling headaches. Investigators hypothesized that the combination of haloperidol and diphenhydramine would be a useful medication choice for migraine headache patients in the emergency department in comparison to a common migraine treatment regimen of metoclopramide and diphenhydramine.


Description:

Investigators conducted a prospective, double-blind, randomized controlled trial in migraine patients who presented to an academic emergency department between June 2013 and November 2013. Research data was derived from an IRB approved protocol. All subjects met IHS migraine criteria and received a one liter bolus of normal saline plus 25 milligrams (mg) of diphenhydramine. Subjects were subsequently randomized to receive 10 mg metoclopramide or 5 mg haloperidol IV. Pain was self-reported at onset and at 20 minute intervals using a 100mm visual analog scale (VAS). Adequate pain control was considered to be patient satisfaction with symptomatic relief. If adequate pain relief was not obtained after 80 minutes, rescue medication was given at the treating physician's discretion. Adverse reactions were recorded and electrocardiograms (ECGs) were obtained before and after study medication administration. Follow up phone surveys were performed 72 hours after discharge to assess headache recurrence, adverse effects, and patient satisfaction.


Recruitment information / eligibility

Status Completed
Enrollment 68
Est. completion date February 2014
Est. primary completion date February 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

Migraine Headache must contain the following:

- At least two: Unilateral, Throbbing, Worsening with activity, Moderate to severe pain

- At least one: Nausea or Vomiting, Photophobia or phonophobia

- Ages 18-50

Exclusion Criteria:

- Hypersensitivity to haloperidol, metoclopramide, and/or diphenydramine

- History of ischemic heart disease or signs or symptoms of ischemic heart disease

- History of stroke or transient ischemic attack (TIA)

- History of peripheral vascular disease

- History of uncontrolled hypertension with presenting diastolic blood pressure > 100

- Use of an ergotamine derivatives, triptan, or dopamine-blocking anti-emetic within the past 24 hrs

- Concurrent administration or within 2 weeks of discontinuing an MAO inhibitor

- Concurrent management of hemiplegic or basilar migraine or known neurologic disorder

- Severe hepatic impairment

- Pregnancy or breastfeeding

- History of cancer (except non-melanoma skin cancer)

- Previous involvement in the study

- Febrile to 100.5 or greater

- Any indication for further diagnostic evaluation of this headache such as a lumbar puncture or CT scan.

- Headache differs from their normal headache

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
Haloperidol
5mg IV
Metoclopramide 10mg
10mg IV
Diphenhydramine
25mg IV

Locations

Country Name City State
United States Naval Medical Center Portsmouth Portsmouth Virginia

Sponsors (1)

Lead Sponsor Collaborator
United States Naval Medical Center, Portsmouth

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other QT prolongation caused by the administration of Haloperidol EKGs were performed prior to the administration of study meds and then again at the completion of the study. 2 hours after administration of Haldol Yes
Primary Pain scores on the visual analog scale 20, 40, 60, and 80 min after administration of medications, and then again at the 48-72 hour mark No
Secondary Nausea and restlessness scores on the visual analog scales 20, 40, 60, and 80 minutes s/p administration of medications, and again 48-72 hours later No
See also
  Status Clinical Trial Phase
Terminated NCT01649258 - Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy Phase 1
Completed NCT02939287 - Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan Phase 3
Not yet recruiting NCT06464926 - Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE) N/A
Not yet recruiting NCT06055192 - Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022
Recruiting NCT04091789 - Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea Phase 2
Completed NCT02462811 - A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV) Phase 3
Completed NCT01007500 - Effect of Dexamethasone Combined With Ondansetron on Postoperative Nausea and Vomiting in Patients With Patient-controlled Analgesia After Video-assisted Thoracoscopic Surgery Phase 4
Recruiting NCT00528554 - Laser Acupuncture Against Nausea in Children N/A
Completed NCT00537875 - Evaluation of the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens N/A
Completed NCT00394966 - A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED) Phase 2
Completed NCT00947128 - To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions Phase 1
Completed NCT00946387 - To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions Phase 1
Recruiting NCT05433636 - Mindful Waiting Room N/A
Not yet recruiting NCT04827108 - Psychometric Properties of the Chinese Version of PeNAT
Not yet recruiting NCT04853303 - VR to Improve CINV, Sleep and Pain Among Children With Cancer in HK N/A
Terminated NCT04247100 - A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders N/A
Recruiting NCT04181346 - Pregabalin for the Prevention of Chemotherapy Induced Nausea and Vomiting Phase 2
Recruiting NCT03679182 - Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care Phase 2
Completed NCT02618343 - EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron N/A
Terminated NCT01405924 - Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030) Phase 2